Browse News
Filter News
Found 12 articles
-
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
1/15/2024
ExeVir Bio announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants.
-
Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors
7/20/2023
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.
-
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
6/28/2023
ExeVir Bio announced it has been awarded a two-year R&D grant of EUR 1.6 million by Flanders Innovation & Entrepreneurship for pre-clinical research towards prophylactic and therapeutic solutions for dengue.
-
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio
4/6/2023
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND", announced it has entered into a collaboration agreement with ExeVir Bio.
-
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
3/13/2023
ExeVir Bio announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike”.
-
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
-
Monoclonal antibodies play a key role in the treatment of COVID-19, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies.
-
XVR011 is being observed in a randomized, double-blind, single-center, and placebo-controlled study to evaluate its pharmacokinetic activity and safety profile.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
-
Money on the Move: March 10-16
3/17/2021
Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week. -
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
-
V-Bio Ventures launches its second fund at EUR 78 million
2/4/2021
V-Bio Ventures (V-Bio) announces today the first closing of V-Bio Fund 2 with capital commitments of EUR 78 million (USD 95 million).